These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6025965)

  • 41. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N; Ullrich D; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1985 Nov; 110(48):1848-51. PubMed ID: 4064938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F; Lessmann J
    Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of phenylhydrazine-induced haemolysis on the urinary excretion of iron after desferrioxamine.
    Cumming RL; Goldberg A; Morrow J; Smith JA
    Lancet; 1967 Jan; 1(7481):71-4. PubMed ID: 4163055
    [No Abstract]   [Full Text] [Related]  

  • 44. [The effect of desferrioxamine on the treatment of transfusion hemosiderosis--with special reference to the method of its administration (authors' transl)].
    Fujiyama N; Nakazawa K
    Rinsho Ketsueki; 1977 Dec; 18(12):1393-400. PubMed ID: 604522
    [No Abstract]   [Full Text] [Related]  

  • 45. [Effect of continuous subcutaneous infusion of deferoxamine in a boy with congenital hypoplastic anemia].
    Ishitoya N; Gomibuchi I; Fujisawa K; Akatsuka J
    Rinsho Ketsueki; 1988 Sep; 29(9):1408-12. PubMed ID: 3216512
    [No Abstract]   [Full Text] [Related]  

  • 46. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M; Economidou J; Karagiorga M; Katsantoni A; Gyftaki E
    Ann N Y Acad Sci; 1974; 232(0):193-200. PubMed ID: 4528481
    [No Abstract]   [Full Text] [Related]  

  • 47. [Use of desferal in anemia, myeloid leukemia and other pathological conditions].
    Kol'tsova GN; Meshchanov AIu
    Gematol Transfuziol; 1992; 37(9-10):44-6. PubMed ID: 1490576
    [No Abstract]   [Full Text] [Related]  

  • 48. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
    Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
    Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 50. The treatment of Cooley's anemia.
    Nathan DG
    Haematologica; 1990; 75 Suppl 5():57-65. PubMed ID: 2086382
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early iron overload in beta-thalassaemia major: when to start chelation therapy?
    Fargion S; Taddei MT; Gabutti V; Piga A; Di Palma A; Capra L; Fontanelli G; Avanzini A
    Arch Dis Child; 1982 Dec; 57(12):929-33. PubMed ID: 7181522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
    Cesana M; Mandelli C; Tiribelli C; Bianchi PA; Conte D
    Am J Gastroenterol; 1989 Feb; 84(2):150-2. PubMed ID: 2916524
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hemochromatosis].
    Phlippen R
    Munch Med Wochenschr; 1972 Feb; 114(5):147-9. PubMed ID: 5066916
    [No Abstract]   [Full Text] [Related]  

  • 55. Intramuscular deferoxamine in hereditary hemochromatosis.
    Polo-Romero FJ
    Am J Hematol; 2006 Mar; 81(3):225-6. PubMed ID: 16493613
    [No Abstract]   [Full Text] [Related]  

  • 56. [Use of deferoxamine-B (Desferal) in the treatment of secondary hemosiderosis in thalassemia major].
    Maspes V; Tamigaki M; Gabriel EA; Moita PR; Jamra M
    Sangre (Barc); 1970; 15(4):435-43. PubMed ID: 5532862
    [No Abstract]   [Full Text] [Related]  

  • 57. Vitamin C and iron.
    Nienhuis AW
    N Engl J Med; 1981 Jan; 304(3):170-1. PubMed ID: 7442737
    [No Abstract]   [Full Text] [Related]  

  • 58. [Diagnosis and therapy of iron overload with desferrioxamine].
    Andres J; Stobbe H
    Z Gesamte Inn Med; 1984 Apr; 39(8):167-9. PubMed ID: 6730593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to long-term deferoxamine therapy in thalassemia.
    Cohen A; Martin M; Schwartz E
    J Pediatr; 1981 Nov; 99(5):689-94. PubMed ID: 7299539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.